Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir plus Sofosbuvir in Genotype 4 HCV
NCT02250807Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Jan 2015; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02250807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250807.